Antiaging Qntum LGN A (AAQL) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 4, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q1 FY2027, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AAQL SEC filings page.
Antiaging Qntum LGN A (AAQL) reported $1.5M in revenue over the twelve months to Jun 30, 2026, up 62.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue is growing, but overhead still exceeds gross profit, leaving a cash-consuming, liability-heavy business despite improved margins.
FY2026 gross profit reached$702K as gross margin rose to67.9% . Yet SG&A was$1.54M , leaving an operating loss of$835K ; the margin step-up reflects better gross economics, but not a business yet sized to absorb its overhead.
Operating cash flow improved from
The balance sheet remains structurally tight: liabilities were
Financial Health Signals
We do not publish a peer-relative financial health score for Antiaging Qntum LGN A, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Antiaging Qntum LGN A scores 5.51, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $34.6M against total liabilities of $2.4M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Antiaging Qntum LGN A passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Antiaging Qntum LGN A reported a net loss of $838K while operations used $171K of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Antiaging Qntum LGN A generated $730K in revenue in Q1 2027. This represents an increase of 150.5% from the same quarter a year earlier. Against the prior quarter it is up 5745.1%.
Antiaging Qntum LGN A's EBITDA was -$313K in Q1 2027, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Antiaging Qntum LGN A reported a net loss of $319K in Q1 2027. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Antiaging Qntum LGN A earned -$0.01 per diluted share (EPS) in Q1 2027. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Antiaging Qntum LGN A held $608K in cash as of Q1 2027; no long-term debt figure is on record for that period.
Not reported for Q1 2027.
Not reported for Q1 2027.
Margins & Returns
Antiaging Qntum LGN A's gross margin was 42.9% in Q1 2027, indicating the percentage of revenue retained after direct costs. This is down 37.7 percentage points from the same quarter a year earlier.
Antiaging Qntum LGN A's operating margin was -44.3% in Q1 2027, reflecting core business profitability. This is up 3.2 percentage points from the same quarter a year earlier.
Antiaging Qntum LGN A's net profit margin was -43.6% in Q1 2027, showing the share of revenue converted to profit. This is up 2.1 percentage points from the same quarter a year earlier.
Not reported for Q1 2027.
Capital Allocation
None of these metrics is reported for Q1 2027.
AAQL Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $730K+150.5% | $12K-95.7% | $340K+120.3% | $390K+125.3% | $291K+44.2% | $288K | $154K+2352.3% | $173K |
| Cost of Revenue | $417K+635.8% | $73K-80.1% | $136K+2543.0% | $66K+357.0% | $57K+34267.3% | $370K | $5K+578.9% | $14K |
| Gross Profit | $313K+33.3% | -$61Kn/m | $204K+36.6% | $324K+104.3% | $235K+16.3% | -$81K | $149K+2595.6% | $159K |
| SG&A Expenses | $636K+70.5% | $313K+219.3% | $476K+36.8% | $376K+5.4% | $373K-10.3% | $98K | $348K+239.2% | $357K+1362.7% |
| Operating Income | -$323Kn/m | -$374Kn/m | -$272Kn/m | -$51Kn/m | -$138Kn/m | -$179Kn/m | -$199Kn/m | -$198Kn/m |
| EBITDA | -$313Kn/m | -$363Kn/m | -$228Kn/m | -$7Kn/m | -$102Kn/m | -$143K | -$163Kn/m | -$146Kn/m |
| Income Tax | N/A | $160 | $55 | $10K | $6K | N/A | N/A | N/A |
| Net Income | -$319Kn/m | -$371Kn/m | -$272Kn/m | -$62Kn/m | -$133Kn/m | -$180Kn/m | -$129Kn/m | -$198Kn/m |
| EPS (Basic) | -$0.01n/m | -$0.01n/m | -$0.01n/m | $0.00n/m | $0.00n/m | -$0.01n/m | $0.00n/m | -$0.01n/m |
| EPS (Diluted) | -$0.01n/m | -$0.01n/m | -$0.01n/m | $0.00n/m | $0.00n/m | -$0.01n/m | $0.00n/m | -$0.01n/m |
| Diluted Shares (Avg) | 34M+14.3% | N/A | 32M+5.7% | 30M+0.2% | 30M0.0% | N/A | 30M0.0% | 30M-0.2% |
Not reported in any period shown, so not listed: R&D Expenses, Interest Expense.
AAQL Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $3.3M+94.9% | $1.7M+8.4% | $1.8M+14.8% | $1.9M+138.8% | $1.7M+59.2% | $1.6M+57.0% | $1.6M+57.8% | $797K+860.9% |
| Current Assets | $2.3M+126.4% | $1.2M+49.8% | $1.3M+92.3% | $1.2M+624.5% | $1.0M+206.6% | $811K+261.5% | $660K+259.9% | $169K+104.3% |
| Cash & Equivalents | $608K+49.9% | $503K+35.9% | $937K+362.7% | $455K+1117.7% | $406K+230.8% | $371K+122.5% | $202K+61.2% | $37K-32.0% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Inventory | $342K | $219K | $102K | $72K | N/A | N/A | N/A | N/A |
| Accounts Receivable | $745K+169.6% | $30K-65.0% | N/A | $468K+1494.8% | $276K+162.4% | $86K+4187.3% | $24K | $29K |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $4.3M+44.6% | $2.4M-11.8% | $2.1M+234.6% | $3.2M+97.6% | $2.9M+75.7% | $2.7M+90.8% | $631K-45.3% | $1.6M+1071.7% |
| Current Liabilities | $2.8M+206.4% | $1.7M+146.8% | $1.4M+277.8% | $1.2M+3.8% | $910K-17.3% | $678K-22.2% | $366K-49.6% | $1.2M+725.8% |
| Non-Current Liabilities | $1.5M-27.8% | $726K-64.5% | $729K | $2.0M+321.7% | $2.0M+253.9% | $2.0M+268.4% | N/A | $484Kn/m |
| Total Equity | -$995Kn/m | -$676Kn/m | -$301K-131.8% | -$1.3Mn/m | -$1.3Mn/m | -$1.1Mn/m | $946Kn/m | -$842Kn/m |
| Retained Earnings | -$2.6Mn/m | -$2.2Mn/m | -$1.9Mn/m | -$1.6Mn/m | -$1.5Mn/m | -$1.4Mn/m | -$1.2Mn/m | -$1.1Mn/m |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
AAQL Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$472Kn/m | -$426Kn/m | $346Kn/m | $93Kn/m | -$185Kn/m | -$333Kn/m | -$344Kn/m | -$9Kn/m |
| Depreciation & Amortization | $10K-71.2% | $11K-69.2% | $44K+21.1% | $44K-14.5% | $36K+74.9% | $36K+434.7% | $36K+45797.5% | $51K+65044.3% |
| Capital Expenditures | N/A | N/A | N/A | N/A | $1K | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | -$186K | N/A | N/A | N/A |
| Investing Cash Flow | N/A | -$17n/m | $3Kn/m | -$164Kn/m | -$1Kn/m | -$19Kn/m | -$15 | -$15K |
| Financing Cash Flow | $573K+160.5% | $0-100.0% | $120K-76.5% | $120Kn/m | $220K+10.1% | $519K+109.5% | $511K-24.6% | -$61K-214.8% |
Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.
AAQL Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 42.9%-37.7pp | -488.3% | 59.9%-36.7pp | 83.2%-8.5pp | 80.5%-19.4pp | -28.3% | 96.7%+8.7pp | 91.7% |
| Operating Margin | -44.3%+3.2pp | -2992.1% | -80.0% | -13.1% | -47.4% | -62.3% | -128.7% | -114.2% |
| Net Margin | -43.6%+2.1pp | -2966.2% | -80.0%+3.6pp | -15.8% | -45.8% | -62.3% | -83.6% | -114.2% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | -13.7% | N/A |
| Return on Assets | -9.8%-1.8pp | -21.5%-10.2pp | -15.0%-6.8pp | -3.2%+21.6pp | -8.0%+12.4pp | -11.3%+14.6pp | -8.2%+1.5pp | -24.8%+4.6pp |
| Current Ratio | 0.83-0.3x | 0.73-0.5x | 0.92-0.9x | 1.02+0.9x | 1.12+0.8x | 1.20+0.9x | 1.80+1.6x | 0.15-0.4x |
| Liabilities-to-Equity | N/A | N/A | N/A | N/A | N/A | N/A | 0.67 | N/A |
| Asset Turnover | 0.220.0x | 0.01-0.2x | 0.19+0.1x | 0.210.0x | 0.170.0x | 0.18 | 0.10+0.1x | 0.22 |
| FCF Margin | N/A | N/A | N/A | N/A | -63.8% | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin.
Note: Shareholder equity is negative (-$676K), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.73), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Antiaging Qntum LGN A AAQL | FY2026 | $1.0M | -$838K | -81.0% | $34.6M | — |
| Kun Peng Intl Ltd KPEA | FY2025 | $1.4M | -$1.3M | -87.8% | $12.8M | — |
| Solo Brands Inc A SBDS | FY2025 | $316.6M | -$101.3M | -32.0% | $7.7M | — |
Where Antiaging Qntum LGN A Ranks
Frequently Asked Questions
Antiaging Qntum LGN A (AAQL) reported $1.0M in total revenue for fiscal year 2026. This represents a 26.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Antiaging Qntum LGN A (AAQL) revenue grew by 26.5% year-over-year, from $818K to $1.0M in fiscal year 2026.
No, Antiaging Qntum LGN A (AAQL) reported a net loss of $1.0M over the trailing 12 months to June 30, 2026. In fiscal year 2026 it reported a net loss of $838K, with a net profit margin of -81.0%.
Antiaging Qntum LGN A (AAQL) had EBITDA of -$701K in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
Antiaging Qntum LGN A (AAQL) had a gross margin of 67.9% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.
Antiaging Qntum LGN A (AAQL) had an operating margin of -80.8% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.
Antiaging Qntum LGN A (AAQL) had a net profit margin of -81.0% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.
Antiaging Qntum LGN A (AAQL) recorded an outflow of $171K in operating cash flow during fiscal year 2026, representing cash used by core business activities.
Antiaging Qntum LGN A (AAQL) had $1.7M in total assets as of fiscal year 2026, including both current and long-term assets.
Antiaging Qntum LGN A (AAQL) had a current ratio of 0.73 as of fiscal year 2026, which is below 1.0, which may suggest potential liquidity concerns.
Antiaging Qntum LGN A (AAQL) had a return on assets of -48.6% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
Antiaging Qntum LGN A (AAQL) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $34.6M as of Nov 4, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Antiaging Qntum LGN A (AAQL) trades at 23.5x sales, its market capitalization divided by $1.5M revenue, trailing 12 months to June 30, 2026. The market capitalization is $34.6M as of Nov 4, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2026, Antiaging Qntum LGN A (AAQL) held $503K in cash, cash equivalents and investments, and reported an operating cash outflow of $171K over that year. Dividing the one by the other, the reported balance equals about 35 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Antiaging Qntum LGN A (AAQL) has negative shareholder equity of -$676K as of fiscal year 2026, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
Antiaging Qntum LGN A (AAQL) has an Altman Z-Score of 5.51, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Antiaging Qntum LGN A (AAQL) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Antiaging Qntum LGN A (AAQL) reported a net loss of $838K while operations used $171K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.